ArticleInfection and immunity2020
The Factor H-Binding Site of CspZ as a Protective Target against Multistrain, Tick-Transmitted Lyme Disease.
Open access · greenAbstract read
In one paragraph
Article in Infection and immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Protective efficacy of mutant strains ofInfection and immunity · 2026Article
- Evaluation of EcoCRM, virus-like particles, and mRNA as vaccine platforms against Borrelia burgdorferi.Vaccine · 2026Article
- Developing a durable, memory-driven, CspZ-targeting Lyme disease vaccine by rational adjuvant selection.NPJ vaccines · 2026Article
- Efficacy of Purified Borrelial Lipoproteins (PBL) as an oral formulation in reducing transmission of Lyme spirochetes from reservoir hosts tobioRxiv : the preprint server for biology · 2026Article
- From forest floor to doctor's office: the immunological journey ofFrontiers in immunology · 2026Review
- Complement therapeutic factor H-IgG proteins as pre-exposure prophylaxes against Lyme borreliae infections.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccine.Nature communications · 2025Article
- CspZ variant-specific interaction with factor H incorporates a metal site to support Lyme borreliae complement evasion.The Journal of biological chemistry · 2025Article
- Mechanistic insights into structure-based design of a Lyme disease subunit vaccine.bioRxiv : the preprint server for biology · 2024Article
- Complement therapeutic Factor H-IgG proteins as pre-exposure prophylaxes against Lyme borreliae infections.bioRxiv : the preprint server for biology · 2024Article
- Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches.The Journal of infectious diseases · 2024Review
- Production, purification, and quality assessment of borrelial proteins CspZ from Borrelia burgdorferi and FhbA from Borrelia hermsii.Applied microbiology and biotechnology · 2024Article
- Impact ofFrontiers in immunology · 2024Article
- Structural evolution of an immune evasion determinant shapes pathogen host tropism.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.Expert review of vaccines · 2022Review
- CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance.Infection and immunity · 2022Article
- Immune Response toCurrent issues in molecular biology · 2021Article
- Hijacking Factor H for Complement Immune Evasion.Frontiers in immunology · 2021Review
- Human and Veterinary Vaccines for Lyme Disease.Current issues in molecular biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 3 countries.
Ashley L Marcinkiewicz *Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
Ilva LiekninaLatvian Biomedical Research and Study Centre, Riga, Latvia.
Xiuli YangDepartment of Veterinary Medicine, Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
Patricia L LedermanDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
Thomas M HartDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
Jennifer YatesDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.
Wen-Hsiang ChenDepartment of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA.
Maria Elena BottazziDepartment of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA.
Nicholas J MantisDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA.ORCID 0000-0002-5083-8640
Peter KraiczyInstitute of Medical Microbiology and Infection Control, University Hospital of Frankfurt, Frankfurt, Germany.
Utpal PalDepartment of Veterinary Medicine, Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.
Kaspars TarsLatvian Biomedical Research and Study Centre, Riga, Latvia.
Yi-Pin Lin *Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, New York, USA Yi-Pin.Lin@health.ny.gov.ORCID 0000-0002-5240-2031
New York State Department of Health · USLatvian Biomedical Research and Study Centre · LVVirginia–Maryland College of Veterinary Medicine · USBaylor College of Medicine · USBaylor University · USGoethe University Frankfurt · DE
Funding
Tickborne Disease: B cell epitope discovery and mechanisms of antibody Protection75N93019C00040 · NIAID · NYSDOH/HEALTH RESEARCH, INC. · PI MANTIS, NICHOLAS J. · 2019 to 2023
$10.3MBORRELIA GENE PRODUCTS CRITICAL FOR NATURAL INFECTION CYCLER01AI080615 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI PAL, UTPAL · 2009 to 2024
$5.2MMultiple B. burgdorferi Factors Collaborate to Evade Complement-Mediated DefensesR01AI121401 · NIAID · TUFTS UNIVERSITY BOSTON · PI COBURN, JENIFER L, LEONG, JOHN M · 2016 to 2020
$3.1MBBA57-Mediated Borrelial Persistence, Genesis of Inflammation and ImmunityR01AI116620 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI PAL, UTPAL · 2015 to 2019
$1.9MIdentification of the mechanism of protection against a B. burgdorferi protein CspZ for the prevention of Lyme diseaseR21AI144891 · NIAID · WADSWORTH CENTER · PI BOTTAZZI, MARIA ELENA, LIN, YI-PIN · 2020 to 2021
$441kNIAID NIH HHS 75N93019C00040NIAID NIH HHS R01 AI080615NIAID NIH HHS R01 AI116620NIAID NIH HHS R01 AI121401NIAID NIH HHS R21 AI144891
Abstract
The spirochete
Indexed as
AnimalsAntibodiesBacterial ProteinsBinding SitesBorrelia burgdorferiComplement Factor HComplement System ProteinsFemaleHumansLyme DiseaseLyme Disease VaccinesMiceMice, Inbred BALB CMice, Inbred C3HTicksAntibodiesBacterial ProteinsComplement Factor HComplement System ProteinsLyme Disease VaccinesBorreliaCspZLyme diseasevaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.